PMID- 29383153
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 70
DP  - 2017 Dec 29
TI  - Reciprocal crosstalk between endometrial carcinoma and mesenchymal stem cells via 
      transforming growth factor-beta/transforming growth factor receptor and C-X-C motif 
      chemokine ligand 12/C-X-C chemokine receptor type 4 aggravates malignant 
      phenotypes.
PG  - 115202-115214
LID - 10.18632/oncotarget.23212 [doi]
AB  - Designated for cyclic shedding, the endometrial stroma is rich in endometrial 
      mesenchymal stem cells (EMSCs) and may play an important role in the development 
      of endometrial carcinoma (EC). This study characterized the crosstalk of EC cells 
      with EMSCs and the resultant effects on malignant phenotypes. The cultured EMSCs 
      expressed CD73, CD90, and CD105, but not CD14, CD19, CD34, CD45, or human 
      leukocyte antigen-antigen D related markers. These EMSCs also showed osteogenic, 
      adipogenic, and chondrogenic differentiation ability. Transforming growth factor 
      (TGF)-beta1 and C-X-C motif chemokine ligand 12 (CXCL12) secretion or expression 
      were reciprocally enhanced in EC cells and EMSCs, as well as in their tissues. By 
      acting on the receptors expressed in their mutual target cells, the interaction 
      between TGF-beta and CXCL12 results in the enhanced migration, invasion, 
      tumorigenesis, and epithelial-mesenchymal transition of EC cells, which can be 
      blocked by neutralizing the antibody of either CXCL12 or C-X-C chemokine receptor 
      type 4. The study revealed unprecedented paracrine interactions between EC cells 
      and EMSCs that resulted in the enhancement of transformation phenotypes. Thus, 
      the blocking of TGF-beta or CXCL12 signaling can be a therapeutic target for EC.
FAU - Ding, Dah-Ching
AU  - Ding DC
AD  - Department of Obstetrics and Gynecology, Buddhist Tzu-Chi General Hospital, 
      Hualien, Taiwan.
AD  - Institute of Medical Sciences, Tzu Chi University; Hualien, Taiwan.
FAU - Chu, Tang-Yuan
AU  - Chu TY
AD  - Department of Obstetrics and Gynecology, Buddhist Tzu-Chi General Hospital, 
      Hualien, Taiwan.
AD  - Institute of Medical Sciences, Tzu Chi University; Hualien, Taiwan.
AD  - Cervical Cancer Prevention Center, Department of Research, Buddhist Tzu Chi 
      General Hospital, Hualien, Taiwan.
FAU - Liu, Hwan-Wun
AU  - Liu HW
AD  - Institute of Medical Sciences, Tzu Chi University; Hualien, Taiwan.
AD  - Department of Occupational Medicine, Buddhist Tzu Chi General Hospital, Hualien, 
      Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20171214
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5777765
OTO - NOTNLM
OT  - C-X-C chemokine receptor type 4
OT  - C-X-C motif chemokine ligand 12
OT  - endometrial cancer
OT  - mesenchymal stem cells
OT  - transforming growth factor-ss1
COIS- CONFLICT OF INTEREST The authors have no conflicts of interest to declare.
EDAT- 2018/02/01 06:00
MHDA- 2018/02/01 06:01
PMCR- 2017/12/29
CRDT- 2018/02/01 06:00
PHST- 2016/12/14 00:00 [received]
PHST- 2017/08/06 00:00 [accepted]
PHST- 2018/02/01 06:00 [entrez]
PHST- 2018/02/01 06:00 [pubmed]
PHST- 2018/02/01 06:01 [medline]
PHST- 2017/12/29 00:00 [pmc-release]
AID - 23212 [pii]
AID - 10.18632/oncotarget.23212 [doi]
PST - epublish
SO  - Oncotarget. 2017 Dec 14;8(70):115202-115214. doi: 10.18632/oncotarget.23212. 
      eCollection 2017 Dec 29.